



Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 3, 2024

PASADENA, Calif.--(BUSINESS WIRE)--Jan. 3, 2024-- Xencor, Inc. (NASDAQ:XCOR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024 at 3:45 p.m. PST.

A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. After the webcast, a replay will be archived on the website for at least 30 days.

About Xencor

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb[®] technology are in clinical development, and three XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein's structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240103100031/en/): <https://www.businesswire.com/news/home/20240103100031/en/>

Charles Liles
cliles@xencor.com
626-737-8118

Source: Xencor, Inc.